Patients with a histologically or cytologically proven diagnosis of NSCLC 
Unresectable (locally advanced) stage IIIa or IIIb disease 
Initial radiotherapy field of treatment to encompass greater than or equal to 30% of the esophagus 
Life expectancy greater than or equal to 6 months 
Estimated weight loss less than or equal to 10% in the 3 months before study randomization 
Measurable disease 
18 years of age or older 
Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2 
Hemoglobin (hgb) greater than or equal to 10 g/dL without transfusional support or growth factor use in the 4 weeks before study randomization 
Absolute neutrophil count (ANC) greater than or equal to 1.5 x 10^9/L without growth factor use in the 2 weeks before study randomization 
Platelet count greater than or equal to 100 x 10^9/L 
Serum bilirubin less than or equal to 1.5 x institutional upper limit of normal (ULN) 
Serum creatinine less than or equal to 2.0 mg/dL (Note: Patients with a serum creatinine greater than or equal to 1.4 and less than or equal to 2.0 mg/dL must demonstrate a 24-hour urinary creatinine clearance greater than or equal to 50 mL/min) 
Females of childbearing potential: negative serum or urine pregnancy test 
Patient must give written informed consent before participating in any study-specific procedure, randomization, or receiving investigational product. 
Patients with reproductive capability must agree to practice adequate contraception methods. 
